Skip to main content
SpringerLink
Log in

Modulatory effect on dyslipidemia and anti-atherosclerotic function of Xuezhikang in newly diagnosed type 2 diabetes patients

  • Research Article
  • Published:
Frontiers of Medicine in China Aims and scope Submit manuscript

Abstract

The modulatory effect of Xuezhikang on dyslipidemia and the preventive effect on atherosclerosis in newly diagnosed type 2 diabetic patients were studied. A prospective clinical trial was conducted to test the effectiveness of Xuezhikang in selected 201 newly diagnosed type 2 diabetic patients. All patients were randomly divided into two groups: 108 with Xuezhikang therapy and 93 without Xuezhikang therapy. The mean follow-up period was 22 months. The blood glucose and blood pressure of all patients were under control. Serum levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) were significantly lowered and their decreased percentages were significantly higher in Xuezhikang therapy group (P < 0.05). The number of patients with arteria iliaca intima thickening was significantly lower in group of Xuezhikang therapy (P = 0.024). With stepwise multivariate logistic regression analysis, the decreased percentage of TG was significantly and independently related with the decreased number of patients with arteria iliaca intima thickening (P = 0.005). The study demonstrates that Xuezhikang therapy is effective on modulating dyslipidemia in newly diagnosed type 2 diabetes patients, and may be related with the improvement of early atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stevens R J, Kothari V, Adler A I, Stratton I M, United Kingdom Prospective Diabetes Study(UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond), 2001, 101(6): 671–679

    Article  CAS  Google Scholar 

  2. Lu Z L, Du B M, Chen Z H, Wu Y F, Yu X H, Zhao Y C. (represent the effect of Xuezhikang regulating the blood fat to China Coronary Secondary Prevention Study Collaborative group). China Coronary Secondary Prevention Study (CCSPS)—analysis result of patients with type 2 diabetes. Zhonghua Xin Xue Guan Bing Za Zhi, 2005, 33(2): 1067–1070 (in Chinese)

    PubMed  Google Scholar 

  3. Zhang M L, Duan Z W, Xie S M. The Xuezhikang active component study. Zhongguo Xin Yao Za Zhi, 1990, 43(12): 1624 (in Chinese)

    Google Scholar 

  4. Chen Y C, Zhao S P, Liu L, Liu M H, Li Y L. Influence of lipid-modulating therapy on high-fat diet induce endothelial dysfunction in patients with coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi, 2004, 32(2): 114–117 (in Chinese)

    Google Scholar 

  5. Xu B P, Chen Y L, Lu X. The effect of Xuezhikang on oxidation of low density lipoproteins in virto. Zhonghua Nei Ke Za Zhi, 1999, 38(8): 520–522 (in Chinese)

    PubMed  CAS  Google Scholar 

  6. Huang Y, Chen Y Z, Shi R F, Deng G L. Inhibiting effects of Xuezhikang on Monocytes adhesion in the patients with hypercholesterolemia. Zhongguo Dong Mai Ying Hua Za Zhi, 2002, 10(1): 53–55 (in Chinese)

    Google Scholar 

  7. Wu Y J, Yu H, Qin X W, Wang X Y, Sun Y H, Chen J L, Kou W R, Lu Z L. Small dense low-density lipoprotein in different type of hyperlipidimia: Effect of lipid-lowering therapy. Zhongguo Xun Huan Za Zhi, 2002, 17(6): 431–433 (in Chinese)

    Google Scholar 

  8. Zhang P H, Li P, Han X N, Zhang X C, Chen L Y. Inhibitory effect of Xuezhikang on matrix metalloproteinase-2 secreted by macrophage. Zhonghua Xin Xue Guan Bing Za Zhi, 2001, 29(8): 497–499 (in Chinese)

    Google Scholar 

  9. Zhao S P, Liu L, Cheng Y C, Li Y L. Effect of Xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis, 2003, 168(2): 375–380

    Article  PubMed  CAS  Google Scholar 

  10. Zhao S P, Lu Z L, Du B M, Chen Z, Wu Y F, Yu X H, Zhao Y C, Liu L, Ye H J, Wu Z H. Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: Subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol, 2007, 49(2): 1–4

    Article  CAS  Google Scholar 

  11. Laakso M. Diabetes and cardiovascular disease in type 2 diabetes: Challenge for treatment and prevention. J Intern Med, 2001, 249(3): 225–235

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology & Metabolism, Beijing Hospital, Ministry of Healthy, Beijing, 100730, China

    Mingxiao Sun, Yao Wang & Jiamin Chi

Authors
  1. Mingxiao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiamin Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Collaborative Group of National “the 10 five-year project”: Type 2 Diabetes and its Complications Prevention Study

Additional information

__________

Translated from Chinese Journal of Geriatrics, 2007, 26(8): 584–586 [译自: 中华老年医学杂志]]

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sun, M., Wang, Y., Chi, J. et al. Modulatory effect on dyslipidemia and anti-atherosclerotic function of Xuezhikang in newly diagnosed type 2 diabetes patients. Front. Med. China 2, 174–177 (2008). https://doi.org/10.1007/s11684-008-0032-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-008-0032-z

Keywords

Search

Navigation